Jun 10, 2020 / 06:10PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And with us today, we have Gritstone. And we're pleased to have Andrew Allen, CEO of the company. And with that, Andrew, I'm going to turn it over to you to make opening remarks and go through some slides, and then we'll move to Q&A.
Andrew R. Allen - Gritstone Oncology, Inc. - Co-Founder, President, CEO & Director
Sounds good. Thank you, Salveen. Good afternoon, everybody. Pleasure to be with you virtually. My name, indeed, is Andrew Allen. I'm the CEO, and one of the founders of Gritstone Oncology. And I'll begin just by walking through a handful of slides just to orient you with where we're at in our exciting clinical development program around neoantigen-based immunotherapy. I'll be making some forward-looking statements on these few slides.
At a high level, Gritstone has built a pipeline of therapeutics aimed at cancer-specific antigens. Neoantigens were described a few years ago as the key
Gritstone Oncology Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers